Medical Microbiology and Immunology

, Volume 201, Issue 3, pp 277–286

Antiviral function and efficacy of polyvalent immunoglobulin products against CMV isolates in different human cell lines

  • K. Frenzel
  • S. Ganepola
  • D. Michel
  • E. Thiel
  • D. H. Krüger
  • L. Uharek
  • J. Hofmann
Original Paper

Abstract

Primary infection and reactivation of human cytomegalovirus (CMV) remain a major problem in immunocompromised patients, frequently resulting in a life threatening CMV disease. Intravenous polyvalent (hyper)-immunoglobulins (IVIG) can be administered for therapy and prophylaxis of CMV infections. However, only limited data about the efficacy and mechanism of action of IVIG products against viral infections in vitro are available so far. In this study, the effect of IVIG on CMV infection in vitro was investigated using isolates from CMV-infected patients as well as the laboratory strains AD169 and TB40. A qualitative and quantitative comparison of five different commercially available IVIG products in different human cell lines was performed concerning their ability (1) to neutralize cell-free virus, (2) to inhibit cell-to-cell spread and cell-associated transmission and (3) to influence CMV mRNA levels. All IVIG tested exhibited a high neutralization activity in epithelial and endothelial cell cultures (50% inhibition dose <0.1 mg/ml). However, qualitative differences between the products could be demonstrated in neutralization tests using human embryonal lung fibroblasts (HELF). The IVIG products also significantly differed in their ability to inhibit cell-to-cell spread within an CMV-infected HELF monolayer displaying inhibition rates that varied between 61 and 100%. No correlation between the ability to neutralize cell-free virus and to inhibit cell-to-cell spread could be observed. The incubation with IVIG influenced the amount of CMV immediate early and late mRNA, as indicated by a significant reduction in CMV mRNA in infected epithelial cells after incubation with IVIG in a dose-dependent manner. This study suggests different antiviral functions of polyvalent IVIG and confirms their potential to inhibit a CMV infection in vitro, with profound differences between the hereby used IVIG products.

Keywords

Polyvalent immunoglobulins CMV Neutralization mRNA 

References

  1. 1.
    Boeckh M, Leisenring W, Riddell SR et al (2003) Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity. Blood 101:407–414PubMedCrossRefGoogle Scholar
  2. 2.
    Boeckh M, Ljungman P (2009) How we treat cytomegalovirus in hematopoietic cell transplant recipients. Blood 113:5711–5719PubMedCrossRefGoogle Scholar
  3. 3.
    Mercorelli B, Sinigalia E, Loregian A, Palu G (2008) Human cytomegalovirus DNA replication: antiviral targets and drugs. Rev Med Virol 18:177–210PubMedCrossRefGoogle Scholar
  4. 4.
    Li CR, Greenberg PD, Gilbert MJ, Goodrich JM, Riddell SR (1994) Recovery of HLA-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant: correlation with CMV disease and effect of ganciclovir prophylaxis. Blood 83:1971–1979PubMedGoogle Scholar
  5. 5.
    Ljungman P, Cordonnier C, Einsele H et al (1998) Use of intravenous immune globulin in addition to antiviral therapy in the treatment of CMV gastrointestinal disease in allogeneic bone marrow transplant patients: a report from the European group for blood and marrow transplantation (EBMT). Infectious diseases working party of the EBMT. Bone Marrow Transpl 21:473–476CrossRefGoogle Scholar
  6. 6.
    Alexander BT, Hladnik LM, Augustin KM et al (2010) Use of cytomegalovirus intravenous immune globulin for the adjunctive treatment of cytomegalovirus in hematopoietic stem cell transplant recipients. Pharmacotherapy 30:554–561PubMedCrossRefGoogle Scholar
  7. 7.
    Bonaros N, Mayer B, Schachner T, Laufer G, Kocher A (2008) CMV-hyperimmune globulin for preventing cytomegalovirus infection and disease in solid organ transplant recipients: a meta-analysis. Clin Transpl 22:89–97Google Scholar
  8. 8.
    Siadak MF, Kopecky K, Sullivan KM (1994) Reduction in transplant-related complications in patients given intravenous immuno globulin after allogeneic marrow transplantation. Clin Exp Immunol 97(Suppl 1):53–57PubMedGoogle Scholar
  9. 9.
    Nigro G, Adler SP, La TR, Best AM (2005) Passive immunization during pregnancy for congenital cytomegalovirus infection. N Engl J Med 353:1350–1362PubMedCrossRefGoogle Scholar
  10. 10.
    Nigro G, Torre RL, Pentimalli H et al (2008) Regression of fetal cerebral abnormalities by primary cytomegalovirus infection following hyperimmunoglobulin therapy. Prenat Diagn 28:512–517PubMedCrossRefGoogle Scholar
  11. 11.
    Raanani P, Gafter-Gvili A, Paul M, Ben Bassat I, Leibovici L, Shpilberg O (2009) Immunoglobulin prophylaxis in hematopoietic stem cell transplantation: systematic review and meta-analysis. J Clin Oncol 27:770–781PubMedCrossRefGoogle Scholar
  12. 12.
    Cordonnier C, Chevret S, Legrand M et al (2003) Should immunoglobulin therapy be used in allogeneic stem-cell transplantation? A randomized, double-blind, dose effect, placebo-controlled, multicenter trial. Ann Intern Med 139:8–18PubMedGoogle Scholar
  13. 13.
    Filipovich AH, Peltier MH, Bechtel MK, Dirksen CL, Strauss SA, Englund JA (1992) Circulating cytomegalovirus (CMV) neutralizing activity in bone marrow transplant recipients: comparison of passive immunity in a randomized study of four intravenous IgG products administered to CMV-seronegative patients. Blood 80:2656–2660PubMedGoogle Scholar
  14. 14.
    Lang P, Griesinger A, Hamprecht K et al (2004) Antiviral activity against CMV-infected fibroblasts in pediatric patients transplanted with CD34(+)-selected allografts from alternative donors. Hum Immunol 65:423–431PubMedCrossRefGoogle Scholar
  15. 15.
    Andreoni KA, Wang X, Huang SM, Huang ES (2002) Human cytomegalovirus hyperimmune globulin not only neutralizes HCMV infectivity, but also inhibits HCMV-induced intracellular NF-kappaB, Sp1, and PI3-K signaling pathways. J Med Virol 67:33–40PubMedCrossRefGoogle Scholar
  16. 16.
    Deckers M, Hofmann J, Kreuzer KA et al (2009) High genotypic diversity and a novel variant of human cytomegalovirus revealed by combined UL33/UL55 genotyping with broad-range PCR. Virol J 6:210PubMedCrossRefGoogle Scholar
  17. 17.
    Klein M, Schoppel K, Amvrossiadis N, Mach M (1999) Strain-specific neutralization of human cytomegalovirus isolates by human sera. J Virol 73:878–886PubMedGoogle Scholar
  18. 18.
    Gupta CK, Leszczynski J, Gupta RK, Siber GR (1996) An enzyme immunoassay based micro-neutralization test for titration of antibodies to human cytomegalovirus (CMV) and its correlation with direct ELISA measuring CMV IgG antibodies. Biologicals 24:41–49PubMedCrossRefGoogle Scholar
  19. 19.
    Revello MG, Percivalle E, Arbustini E, Pardi R, Sozzani S, Gerna G (1998) In vitro generation of human cytomegalovirus pp 65 antigenemia, viremia, and leukoDNAemia. J Clin Invest 101:2686–2692PubMedCrossRefGoogle Scholar
  20. 20.
    Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25:402–408PubMedCrossRefGoogle Scholar
  21. 21.
    Voigt S, Mesci A, Ettinger J et al (2007) Cytomegalovirus evasion of innate immunity by subversion of the NKR-P1B: Clr-b missing-self axis. Immunity 26:617–627PubMedCrossRefGoogle Scholar
  22. 22.
    Nichols WG, Corey L, Gooley T, Davis C, Boeckh M (2002) High risk of death due to bacterial and fungal infection among cytomegalovirus (CMV)-seronegative recipients of stem cell transplants from seropositive donors: evidence for indirect effects of primary CMV infection. J Infect Dis 185:273–282PubMedCrossRefGoogle Scholar
  23. 23.
    Marr KA, Carter RA, Boeckh M, Martin P, Corey L (2002) Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood 100:4358–4366PubMedCrossRefGoogle Scholar
  24. 24.
    Aalto SM, Linnavuori K, Peltola H et al (1998) Immunoreactivation of epstein-barr virus due to cytomegalovirus primary infection. J Med Virol 56:186–191PubMedCrossRefGoogle Scholar
  25. 25.
    Gerna G, Sarasini A, Patrone M et al (2008) Human cytomegalovirus serum neutralizing antibodies block virus infection of endothelial/epithelial cells, but not fibroblasts, early during primary infection. J Gen Virol 89:853–865PubMedCrossRefGoogle Scholar
  26. 26.
    Kampmann SE, Schindele B, Apelt L et al (2011) Pyrosequencing allows the detection of emergent ganciclovir resistance mutations after HCMV infection. Med Microbiol Immunol 200:109–113PubMedCrossRefGoogle Scholar
  27. 27.
    Michel D, Wunderlich K, Michel K, Wasner T, Hauser I, Just M, Hampl H, Mertens TH (2003) Fast genotypic identification and estimation of ganciclovir-resistant cytomegalovirus from clinical specimens. In: Scholz M, Prösch S, Cinatl J (eds) New aspects of CMV-related immunopathology. Doerr HW; Frankfurt: Monogr Virol. Karger, Basel, pp 160–170Google Scholar
  28. 28.
    Shibaguchi H, Yamamoto T, Kuroki M, Futagami K (2010) Measurement and assessment of cytomegalovirus of immunoglobulin (Ig) g titer in preparations. Yakugaku Zasshi 130:977–982PubMedCrossRefGoogle Scholar
  29. 29.
    Darenberg J, Soderquist B, Normark BH, Norrby-Teglund A (2004) Differences in potency of intravenous polyspecific immunoglobulin G against streptococcal and staphylococcal superantigens: implications for therapy of toxic shock syndrome. Clin Infect Dis 38:836–842PubMedCrossRefGoogle Scholar
  30. 30.
    Darenberg J, Ihendyane N, Sjolin J et al (2003) Intravenous immunoglobulin G therapy in streptococcal toxic shock syndrome: a European randomized, double-blind, placebo-controlled trial. Clin Infect Dis 37:333–340PubMedCrossRefGoogle Scholar
  31. 31.
    Johnson S, Oliver C, Prince GA et al (1997) Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J Infect Dis 176:1215–1224PubMedCrossRefGoogle Scholar
  32. 32.
    Krawczyk A, Krauss J, Eis-Hubinger AM et al (2011) Impact of valency of a glycoprotein B-specific monoclonal antibody on neutralization of herpes simplex virus. J Virol 85:1793–1803PubMedCrossRefGoogle Scholar
  33. 33.
    Isaacson MK, Compton T (2009) Human cytomegalovirus glycoprotein B is required for virus entry and cell-to-cell spread but not for virion attachment, assembly, or egress. J Virol 83:3891–3903PubMedCrossRefGoogle Scholar
  34. 34.
    Li L, Coelingh KL, Britt WJ (1995) Human cytomegalovirus neutralizing antibody-resistant phenotype is associated with reduced expression of glycoprotein H. J Virol 69:6047–6053PubMedGoogle Scholar
  35. 35.
    Britt WJ, Vugler L, Butfiloski EJ, Stephens EB (1990) Cell surface expression of human cytomegalovirus (HCMV) gp55-116 (gB): use of HCMV-recombinant vaccinia virus-infected cells in analysis of the human neutralizing antibody response. J Virol 64:1079–1085PubMedGoogle Scholar
  36. 36.
    Gerna G, Percivalle E, Baldanti F et al (2000) Human cytomegalovirus replicates abortively in polymorphonuclear leukocytes after transfer from infected endothelial cells via transient microfusion events. J Virol 74:5629–5638PubMedCrossRefGoogle Scholar
  37. 37.
    Yurochko AD, Kowalik TF, Huong SM, Huang ES (1995) Human cytomegalovirus upregulates NF-kappa B activity by transactivating the NF-kappa B p105/p50 and p65 promoters. J Virol 69:5391–5400PubMedGoogle Scholar
  38. 38.
    Yurochko AD, Hwang ES, Rasmussen L, Keay S, Pereira L, Huang ES (1997) The human cytomegalovirus UL55 (gB) and UL75 (gH) glycoprotein ligands initiate the rapid activation of Sp1 and NF-kappaB during infection. J Virol 71:5051–5059PubMedGoogle Scholar
  39. 39.
    Bentz GL, Yurochko AD (2008) Human CMV infection of endothelial cells induces an angiogenic response through viral binding to EGF receptor and beta1 and beta3 integrins. Proc Natl Acad Sci USA 105:5531–5536PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2012

Authors and Affiliations

  • K. Frenzel
    • 1
  • S. Ganepola
    • 2
    • 4
  • D. Michel
    • 3
  • E. Thiel
    • 2
  • D. H. Krüger
    • 1
  • L. Uharek
    • 2
  • J. Hofmann
    • 1
  1. 1.Institute of Medical Virology, Helmut-Ruska-Haus, Charité University MedicineBerlinGermany
  2. 2.Department of Haematology, Oncology and Transfusion MedicineCharité University MedicineBerlinGermany
  3. 3.Institute of VirologyUniversity Hospital UlmUlmGermany
  4. 4.Department of Haematology, Oncology, Stem Cell TransplantationAsklepios Klinik AltonaHamburgGermany

Personalised recommendations